Clinical Trial News and Research

RSS

Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of castration-resistant prostate cancer. ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed by both companies for the treatment of solid tumors.

21 Oct 2010

Researchers to study effect of reovirus on cancer cells

A common virus that can cause coughing and mild diarrhea appears to have a major redemptive quality: the ability to kill cancer. Harnessing that power, researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center, are conducting a clinical trial to see if the virus can target and kill certain tumor types.

21 Oct 2010

Generex announces participation in Annual Canadian Diabetes Association Conference

Generex Biotechnology Corporation today announced that it will be attending the 13th Annual Canadian Diabetes Association (CDA)/ Canadian Society of Endocrinology and Metabolism (CSEM)Professional Conference and Annual Meetings in Edmonton, Alberta. The gathering will run from October 20-23, 2010 at the Shaw Conference Centre.

21 Oct 2010

DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy

MacroGenics, Inc. and Eli Lilly and Company today announced that the Protege Data Monitoring Committee (DMC), composed of independent experts in the fields of diabetes and biostatistics, has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab, an investigational biologic under development for the treatment of individuals with recent-onset type 1 diabetes.

21 Oct 2010

Genzyme third quarter revenue increases to $1.0 billion

Genzyme Corp. today reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter. Earnings growth in the third quarter was also driven by strong revenue from Lumizyme™ (alglucosidase alfa) and cost reduction measures.

21 Oct 2010

Genzyme reports results of Clolar combination Phase 3 trial in adult AML

Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).

21 Oct 2010

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from seven hospital Institutional Review Boards in India to begin enrollment of subjects for a Phase III clinical trial of Multikine, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

21 Oct 2010

Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy

Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD916, a novel drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy.

20 Oct 2010

European Commission grants Ipsen's OBI-1 orphan drug status for treatment of hemophilia

Ipsen announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia. Expected to enter pivotal clinical trials before the end of this year, OBI-1 is designed to treat individuals with hemophilia who have developed inhibitory antibodies (inhibitors) against human Factor VIII (hFVIII).

20 Oct 2010

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The vaccine represents a novel strategy for fighting the virus that causes AIDS by attempting to address one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity.

20 Oct 2010

Retina Implant's first clinical trial results presented at 2010 AAO annual meeting

Retina Implant AG, a leading developer of subretinal implants for the visually impaired, is proud to announce Co-Founder and Chairman Eberhart Zrenner, M.D. was invited to present the exciting results of clinical trials he has been leading since 2005 by the American Academy of Ophthalmology at this year's annual meeting that took place October 16-19 at McCormick Place in Chicago, Ill.

20 Oct 2010

Highlights of world's largest ophthalmic education conference

Results of clinical research on new presbyopia treatments now available in Europe-and possibly available soon in the United States-were reported in today's Scientific Program of the 2010 Joint Meeting of the American Academy of Ophthalmology (AAO) and Middle East-Africa Council of Ophthalmology (MEACO). The AAO-MEACO meeting is the world's largest, most comprehensive ophthalmic education conference and is in session October 16 through 19 at McCormick Place, Chicago.

20 Oct 2010

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

20 Oct 2010

UTHSC-Houston initiates enrollment in NanoLogix technology trial for detection of GBS in pregnant women

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, announced today that the University of Texas Health Science Center in Houston is enrolling 300 patients in an ongoing clinical trial to study the speed and accuracy of NanoLogix technology. The trial is designed to compare NanoLogix technology to current methods in use for detection and identification of Group B Streptococcus (GBS) in pregnant women.

20 Oct 2010

UH researchers to explore role of Vitamin D in esophageal cancer prevention

In a first-of-its-kind clinical trial, physicians at University Hospitals (UH) Case Medical Center who are Case Western Reserve University School of Medicine researchers are exploring the role of Vitamin D in preventing esophageal cancer.

20 Oct 2010

Particle Sciences enters licensing, technology agreement with Solubest

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO and SoluBest have entered into a licensing and technology development agreement. Under the agreement, Particle Sciences will be the exclusive contract research provider in the U.S. for SoluBest's Solumer technology.

20 Oct 2010

Japanese study finds proton beam therapy safe and effective for Stage I inoperable NSCLC

Proton beam therapy is safe and effective and may be superior to other conventional treatments for Stage I inoperable non-small cell lung cancer (NSCLC) patients, according to a study in the October issue of the International Journal of Radiation Oncology•Biology•Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

20 Oct 2010

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

Adamis Pharmaceuticals Corporation today announced the completion of the acquisition from Colby Pharmaceuticals of the remaining exclusive license agreements relating to two drug product candidates for the treatment of prostate cancer (PCa).

20 Oct 2010

MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma

MannKind Corporation today announced the first patient has been dosed in a phase 2 clinical trial of the novel, investigational cancer vaccine MKC1106-MT. As a part of MannKind's cancer immunotherapy program, this phase 2 study will evaluate the safety, tolerability, immune response and clinical response of MKC1106-MT in patients with advanced melanoma.

20 Oct 2010

Research paves way to understand the mechanism of leptin therapy to improve type 1 diabetes

New findings by UT Southwestern Medical Center researchers suggest a novel role for the brain in mediating beneficial actions of the hormone leptin in type 1 diabetes.

20 Oct 2010

Clinical Trial News and Research

Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer

Researchers to study effect of reovirus on cancer cells

Generex announces participation in Annual Canadian Diabetes Association Conference

DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy

Genzyme third quarter revenue increases to $1.0 billion

Genzyme reports results of Clolar combination Phase 3 trial in adult AML

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy

European Commission grants Ipsen's OBI-1 orphan drug status for treatment of hemophilia

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

Retina Implant's first clinical trial results presented at 2010 AAO annual meeting

Highlights of world's largest ophthalmic education conference

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

UTHSC-Houston initiates enrollment in NanoLogix technology trial for detection of GBS in pregnant women

UH researchers to explore role of Vitamin D in esophageal cancer prevention

Particle Sciences enters licensing, technology agreement with Solubest

Japanese study finds proton beam therapy safe and effective for Stage I inoperable NSCLC

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma

Research paves way to understand the mechanism of leptin therapy to improve type 1 diabetes

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery